Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease

Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease

25 Jun 2023

Use of pembrolizumab is well tolerated in nonsmall cell lung cancer (NSCLC) patients with previous autoimmune diseases, with a nonsignificant trend toward improved outcomes, reports a study.

Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease

25 Jun 2023